Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation - PowerPoint PPT Presentation

Loading...

PPT – Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation PowerPoint presentation | free to download - id: 78ae3a-NmNhO



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Description:

The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; GBI Research analysis identified 253 first-in-class programs in the breast cancer pipeline, acting on 176 first-in-class molecular targets. Browse complete report with TOC: – PowerPoint PPT presentation

Number of Views:13

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation


1

Frontier Pharma Breast Cancer - Identifying and
Commercializing First-in-Class Innovation

Published By GBI Research
Published May 2014
2
Description


Exceptionally Large and Innovative Pipeline The
breast cancer pipeline is the largest in the
pharmaceutical industry with 815 products in
active development across all stages. The range
of mechanisms of action employed by these
compounds is also highly diverse, especially in
comparison to the existing market landscape. More
pertinently, the degree and proportion of
breakthrough innovations in this pipeline is
exceptional GBI Research analysis identified 253
first-in-class programs in the breast cancer
pipeline, acting on 176 first-in-class molecular
targets. This accounts for some 39 of all
products with a disclosed molecular target and is
reflective of the high degree of innovation in
this indication. This has far-reaching strategic
implications for all market participants, as,
despite the high attrition rate in breast cancer,
it is highly likely many of the first-in-class
technologies will reach the market over the
coming decade and may transform the clinical and
commercial landscape.
3
Description


Scope The report analyzes innovation in breast
cancer, in the context of the overall pipeline
and current market landscape. In addition, it
analyzed the deals landscape surrounding
first-in-class products in breast cancer, and
pinpoints opportunities for in-licensing. The
report covers and includes - - A brief
introduction to breast cancer, including
symptoms, pathophysiology, and overview of
pharmacotherapy and treatment algorithms. - The
changing molecular target landscape between
market and pipeline and particular focal points
of innovation in the pipeline. - Comprehensive
review of the pipeline for first-in-class
therapies, analyzed on the basis of stage of
development, molecule type and molecular
target. - Identification and assessment of
first-in-class molecular targets with a
particular focus on early-stage programs of which
clinical utility has yet to be evaluated, as well
as literature reviews on novel molecular targets.
4
Description

Reasons to buy The report will assist business
development and enable marketing executives to
strategize their product launches, by allowing
them to - - Understanding of the focal shifts in
molecular targets in the breast cancer
pipeline. - Understanding of the distribution of
pipeline programs by phase of development,
molecule type and molecular target. - Access a
scientific and clinical analysis of
first-in-class developmental programs for breast
cancer, benchmarked against non-first-in-class
targets. - Assess the valuations of licensed and
co-developed breast cancer treatments. - Access a
list of the first-in-class therapies potentially
open to deal-making opportunities.
5
Table of Contents

  • 1 Table of Contents
  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2 Executive Summary
  • 2.1 Disease Introduction 
  • 3 The Case for Innovation in the Breast Cancer
    Market
  • 3.1 Temodar (temozolomide) - Merck 
  • 4 Clinical and Commercial Landscape
  • 4.1 Overall Pipeline 
  • 5 Assessment of Pipeline Product Innovation
  • 5.1 Geographical Markets

6
Table of Contents

  • 6 Signaling Network, Disease Causation and
    Innovation Alignment 
  • 7 First-In-Class Target Evaluation
  • 8 Deals and Strategic Consolidations
  • 9 Appendix 
  • For inquiry, kindly contact at
    http//www.reportsandintelligence.com/enquire-abou
    t-report/170667
  • To check table of contents of the research, Visit
    _at_ http//www.reportsandintelligence.com/frontier-
    pharma-breast-cancer-identifying-and-commercializi
    ng-first-in-class-innovation-market/table-of-conte
    nts

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/frontier-pha
rma-breast-cancer-identifying-and-commercializing-
first-in-class-innovation-market
Stay With Us
TELEPHONE Direct 1 (617) 674-4143 Toll Free
1 (855) 711-1555 E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
About PowerShow.com